Dosing regimes for treatment of synucleinopathies
AssigneesProthena Biosciences Limited, Hoffmann-La Roche Inc.
InventorsJay Soto, Daniel Keith Ness, Martin Koller, Diane Mould, Frank Boess, Meret Martin-Facklam, Valerie Cosson, Hans Peter Grimm, Ronald Gieschke, Sara Belli, Silke Weber
Life of this patent
Estimating the term…
Abstract
The invention provides dosage regimes for treatment of synucleinopathies. In one regime, a subject receives 3000-5000 mg of an antibody intravenously every 3-5 weeks. In another regime, a subject receives 1300-1700 mg of an antibody intravenously every 3-5 weeks.
Claims13
A method of treating or effecting prophylaxis of a subject having Parkinson's disease, comprising intravenously administering to the subject a dose of 1500 mg of an antibody or an antigen binding fragment thereof against alpha-synuclein at intervals of 3-5 weeks, wherein the antibody comprises a heavy chain variable region comprising SEQ ID NO:10, respectively, and a light chain comprising SEQ ID NO:5.
Dependencies are inferred from the claim text.